序号38
伊立替康
药代动力学
生物利用度
活性代谢物
药理学
流出
多药耐药蛋白2
化学
腹泻
苯妥英钠
内科学
医学
运输机
ATP结合盒运输机
结直肠癌
生物化学
癌症
癫痫
精神科
基因
作者
Rongjin Sun,Lijun Zhu,Li Li,Wenjie Song,Xia Gong,Xiaoxiao Qi,Ying Wang,Romi Ghose,Song Gao,Ming Hu,Zhongqiu Liu
标识
DOI:10.1016/j.taap.2020.115032
摘要
Irinotecan-induced diarrhea (IID) results from intestinal damages by its active metabolite SN-38. Alleviation of these damages has focused on lowering luminal SN-38 concentrations. However, it is unclear if the enteric bioavailability of SN-38 is mostly dependent on luminal SN-38 concentrations. Irinotecan (50 mg/kg, i.p. once daily for 6 days) was administered to female wildtype FVB, Mdr1a (−/−), Mrp2 (−/−) and Bcrp1 (−/−) mice for pharmacokinetic (PK), toxicokinetic (TK) and biodistribution studies. Plasma PK/TK profiles and tissues drug distribution were determined after first or sixth daily doses, along with activities of blood and gut esterases and intestinal Ugts. Caco-2 cells and bile-cannulate mice were used to further investigate intestinal and biliary disposition of irinotecan and its metabolites. Significant differences in IID severity were observed with the susceptible rank of Bcrp1(−/−) > wildtype FVB > Mdr1a(−/−) > Mrp2(−/−). This rank order did not correlate with biliary excretion rates of SN-38/SN-38G. Rather, the severity was best correlated (R = 0.805) with the intestinal ratio of Css SN-38/SN-38G, a measure of gut Ugt activity. On the contrary, IID was poorly correlated with plasma AUC ratio of SN-38/SN-38G (R = 0.227). Increased intestinal esterase activities due to repeated dosing and gut efflux transporter functionality are the other key factors that determine SN-38 enteric exposures. Intestinal SN-38 exposure is mainly affected by intestinal Ugt activities and blood esterase activities, and strongly correlated with severity of IID. Modulating intestinal SN-38 concentration and gut Ugt expression should be the focus of future studies to alleviate IID.
科研通智能强力驱动
Strongly Powered by AbleSci AI